Evidence map›Paper›PMID 29305416›Full record

Observational studyHaematologica2018

Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.

Thibaud Lefebvre, Niloofar Reihani, Raed Daher, Thierry Billette de Villemeur, Nadia Belmatoug, Christian Rose, Yves Colin-Aronovicz, Hervé Puy, Caroline Le Van Kim, Mélanie Franco and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Clinical Exome Sequencing in Unexplained Hyperferritinemia Reveals Digenic and Oligogenic Inheritance Beyond Iron Homeostasis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  3. Serum hepcidin as a biomarker of treatment response in Gaucher disease.Molecular genetics and metabolism reports · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Hereditary Hyperferritinemia.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Liver involvement in patients with Gaucher disease types I and III.Molecular genetics and metabolism reports · 2020
    Article
  14. Review
  15. Diagnostics (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Thibaud LefebvreUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm U1149 / ERL 8252, Inflammation Research Center (CRI), Laboratory of Excellence GR-Ex, Paris, France.
Niloofar ReihaniUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm, INTS, "Biologie Intégrée du Globule Rouge" Department, Laboratory of Excellence GR-Ex, Paris, France.
Raed DaherUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm U1149 / ERL 8252, Inflammation Research Center (CRI), Laboratory of Excellence GR-Ex, Paris, France.
Thierry Billette de VillemeurSorbonne Universités, UPMC, GRC ConCer-LD and AP-HP, Hôpital Trousseau, Service de Neuropédiatrie, Centre de Référence des Maladies Lysosomales, Paris, France.
Nadia BelmatougHôpitaux Universitaires Paris Nord Val de Seine, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Service de Médecine Interne, Centre de Référence des Maladies Lysosomales, Clichy, France.
Christian RoseUniversité Catholique de Lille, Hôpital Saint Vincent de Paul, Service d'Hématologie, France.
Yves Colin-AronoviczUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm, INTS, "Biologie Intégrée du Globule Rouge" Department, Laboratory of Excellence GR-Ex, Paris, France.
Hervé PuyUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm U1149 / ERL 8252, Inflammation Research Center (CRI), Laboratory of Excellence GR-Ex, Paris, France.
Caroline Le Van KimUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm, INTS, "Biologie Intégrée du Globule Rouge" Department, Laboratory of Excellence GR-Ex, Paris, France.
Mélanie FrancoUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm, INTS, "Biologie Intégrée du Globule Rouge" Department, Laboratory of Excellence GR-Ex, Paris, France.
Zoubida KarimUniversity Sorbonne Paris Cité, Paris Diderot University, Inserm U1149 / ERL 8252, Inflammation Research Center (CRI), Laboratory of Excellence GR-Ex, Paris, France zoubida.karim@inserm.fr.
Biologie Intégrée du Globule Rouge · FRCentre de Recherche sur l'Inflammation · FRAssistance Publique – Hôpitaux de Paris · FRLaboratory of Excellence GR-Ex · FRSorbonne Université · FRUniversité Catholique de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gaucher disease (GD) is an inherited deficiency of glucocerebrosidase leading to accumulation of glucosylceramide in tissues such as the spleen, liver, and bone marrow. The resulting lipid-laden macrophages lead to the appearance of "Gaucher cells". Anemia associated with an unexplained hyperferritinemia is a frequent finding in GD, but whether this pathogenesis is related to an iron metabolism disorder has remained unclear. To investigate this issue, we explored the iron status of a large cohort of 90 type I GD patients, including 66 patients treated with enzyme replacement therapy. Ten of the patients treated with enzyme replacement were followed up before and during treatment. Serum levels of hepcidin, the iron regulatory peptide, remained within the physiological range, while the transferrin saturation was slightly decreased in children. Inflammation-independent hyperferritinemia was found in 65% of the patients, and Perl's staining of the spleen and marrow smear revealed iron accumulation in Gaucher cells. Treated patients exhibited reduced hyperferritinemia, increased transferrin saturation and transiently increased systemic hepcidin. In addition, the hepcidin and ferritin correlation was markedly improved, and, in most patients, the hemoglobin level was normalized. To further explore eventual iron sequestration in macrophages, we produce a Gaucher cells model by treating the J774 macrophage cell line with a glucocerebrosidase inhibitor and showed induced local hepcidin and membrane retrieval of the iron exporter, ferroportin. These data reveal the involvement of Gaucher cells in abnormal iron sequestration, which may explain the mechanism of hyperferritinemia in GD patients. Local hepcidin-ferroportin interaction was involved in this pathogenesis.

Indexed as

AdolescentAdultAgedAged, 80 and overAnimalsCation Transport ProteinsChildChild, PreschoolEnzyme Replacement TherapyFemaleFerritinsFerroportinGaucher DiseaseHepcidinsHumansIronCation Transport ProteinsFerritinsFerroportinHepcidinsIron

Identifiers

PMID29305416
PMCPMC5865418
OpenAlexW2782297009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.